Last A$0.12 AUD
Change Today +0.005 / 4.55%
Volume 1.4M
As of 12:10 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

admedus ltd (AHZ) Snapshot

Open
A$0.11
Previous Close
A$0.11
Day High
A$0.12
Day Low
A$0.11
52 Week High
01/8/14 - A$0.19
52 Week Low
11/5/14 - A$0.09
Market Cap
165.9M
Average Volume 10 Days
3.0M
EPS TTM
A$-0.0059
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADMEDUS LTD (AHZ)

Related News

No related news articles were found.

admedus ltd (AHZ) Related Businessweek News

No Related Businessweek News Found

admedus ltd (AHZ) Details

Admedus Limited, a diversified healthcare company, focuses on developing and commercializing next generation technologies. The company is involved in the process of commercializing its tissue engineering technology for regenerative medicine. It provides CardioCel, a cardiovascular scaffold for the repair and correction of congenital heart deformities, and repair of damaged tissue, including defective heart valves. The company is also developing the next generation vaccines that target diseases, such as herpes and human papillomavirus. In addition, it distributes disposable medical products and medical devices, as well as is involved in the bioimplants and DNA vaccines operations. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Perth, Australia.

admedus ltd (AHZ) Top Compensated Officers

Managing Director, Chief Executive Officer an...
Total Annual Compensation: A$350.9K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$191.5K
Chief Operating Officer
Total Annual Compensation: A$315.3K
Executive Director
Total Annual Compensation: --
Executive
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

admedus ltd (AHZ) Key Developments

Admedus Limited - Shareholder/Analyst Call

Admedus Limited - Shareholder/Analyst Call

Admedus Limited Announces Board Appointments

Admedus Limited announced that it has appointed two new directors to its Board. Mr. John Seaberg and Mr. Wayne Paterson have been appointed as independent, non-executive directors. Mr. Seaberg brings with him 37 years' experience in the international medical devices industry with a strong background in development, sales and marketing. He has been involved in both national and multi-national medical device companies, particularly in the cardiovascular space. Mr. Paterson joins Admedus after 20 years as a senior executive in the international pharmaceutical industry, with extensive managerial and marketing experience to the emerging, European and US markets. From 2007 until May 2014, Mr. Seaberg was Founder, Chairman and CEO of NeoChord Inc. Currently, Mr. Seaberg manages the healthcare consulting practice at Platinum Group. Mr. Paterson has held numerous, senior positions in multi-national companies. Throughout his career, he has been responsible for building businesses throughout the world, as well as mergers and major restructures. From 2007 to 2013, Mr. Paterson held senior positions at Merck Serono. In his most recent position as President of Europe, Canada and Australia, he managed over $3 billion in sales with an operational budget of $500 million. Mr. Paterson also held the position of Global Head of Cardio Metabolic Care and General Medicine, with revenue responsibility of $1.5 billion, and was responsible for all aspects of company strategy, including manufacturing strategies, commercial operations and budgets.

Admedus Ltd Announces Final Results from its Phase I Herpes Simplex Virus (HSV-2) Vaccine Study

Admedus Ltd. announced the final results from its Phase I Herpes Simplex Virus (HSV-2) vaccine study. The trial reached its primary endpoint of safety and also showed that 95% of trial participants met the clinical trial T-cell positive response endpoint, generating a positive T-cell response to HSV-2 vaccine antigens. The T-cell responses observed support the progression of the vaccine into a Phase II study. The Phase I study was undertaken in healthy volunteers who were confirmed sero- negative for the HSV-2 virus, with subjects screened prior to vaccination. The purpose of the study was to explore safety, as well as to examine any immune response. 19 of the 20 study subjects generated a positive T-cell response (HSV-2 cell mediated immunity) as defined in the clinical trial protocol. One study subject in the 3rd lowest dose (100 meg) did not show an immune response.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AHZ:AU A$0.12 AUD +0.005

AHZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AHZ.
View Industry Companies
 

Industry Analysis

AHZ

Industry Average

Valuation AHZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.5x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMEDUS LTD, please visit www.admedus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.